EUVIMEDEUVIMED entdecken
BeobachtungsstudieLeitlinieOpen Access · CC BY 4.0

Physicians and pharmacists’ clinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice

Fahmi Y Al-Ashwal iD, Syed Azhar Syed Sulaiman, Siti Maisharah Sheikh Ghadzi iD, Mohammed Abdullah Kubas, Abdulsalam Halboup iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0280432 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Fahmi Y Al-Ashwal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Science and Technology, Sana'a Yemen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Millions of individuals worldwide use statins, and their significant impact on cardiovascular disease (CVD) has been well-established. However, a lack of knowledge about the up-to-date guideline recommendations regarding statin therapy is a common barrier to implementation in clinical practice. Therefore, the present study aimed to assess the current clinical knowledge about statin therapy and its monitoring parameters. Also, we evaluated the barriers to cholesterol management guideline implementation in Yemen.

Methods

This observational cross-sectional study was conducted over four months, from June/2021 to September/2021, in Sana’a, Yemen. A validated questionnaire was distributed face-to-face to 650 participants (350 physicians and 300 pharmacists). Physicians and pharmacists from governmental and private hospitals and those working in private clinics or community pharmacies were included in the study.

Results

A total of 496 participants filled out the survey, with 22 being excluded due to incomplete data. So, the study has an overall response rate of 72.9% (474). The majority of pharmacists (81.8%) and physicians (78.7%) could not identify the patient group that needed ASCVD risk assessment before statin therapy initiation. Although a significant proportion of respondents knew of the fact that high-intensity statins are recommended for patients with ASCVD (65.4%) and primary hypercholesterolemia (58.4%), the majority of physicians and pharmacists could not identify the high (61.6% and 66.7.3%, respectively) and moderate statin-intensity doses (72.2% and 68.6%, respectively). Only 21.9% of all respondents knew that atorvastatin and rosuvastatin can be administered at any time of the day. Similarly, a low overall rate of respondents (19.6%) knew that atorvastatin does not need dose adjustment in chronic kidney diseases, with a statistically significant difference in knowledge between physicians and pharmacists (12.5% vs. 25.6%, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaHumansAtorvastatinPharmacistsCholesterolGuideline Adherence

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAtorvastatinCholesterol

Autor:innen und Institutionen

  • Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, University of Science and Technology, Sana'a, Yemen.
  • Clinical Pharmacy Department, University of Science and Technology Hospital (USTH), Sana'a, Yemen.
  • School of Pharmacy & Medical Sciences, Lebanese International University (LIU), Sana'a, Yemen.

ORCID-Profile: Fahmi Y Al-Ashwal, Siti Maisharah Sheikh Ghadzi, Abdulsalam Halboup

Förderung

  • University of Science and Technology, Sana'a Yemen

Zitieren

APA

Al-Ashwal, F. Y., Sulaiman, S. A. S., Sheikh Ghadzi, S. M., Kubas, M. A., & Halboup, A. (2023). Physicians and pharmacists’ clinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice. PLOS ONE. https://doi.org/10.1371/journal.pone.0280432

Vancouver

Al-Ashwal FY, Sulaiman SAS, Sheikh Ghadzi SM, Kubas MA, Halboup A. Physicians and pharmacists’ clinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice. PLOS ONE. 2023. doi:10.1371/journal.pone.0280432

BibTeX
@article{AlAshwal2023,
  author = {Al-Ashwal, Fahmi Y and Sulaiman, Syed Azhar Syed and Sheikh Ghadzi, Siti Maisharah and Kubas, Mohammed Abdullah and Halboup, Abdulsalam},
  title = {Physicians and pharmacists’ clinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0280432}
}
Kostenlos starten →